Annelot Jm Meijer

6PUBLICATIONS
46CO-AUTHORS
Infant and child healthCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursGene expression (incl. microarray and other genome-wide approaches)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 22, 2024
Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature.

Annelot J M Meijer, Franciscus A Diepstraten, Marc Ansari

|Apr 07, 2022
A Study on Prevalence and Determinants of Ototoxicity During Treatment of Childhood Cancer (SOUND): Protocol for a Prospective Study.

Franciscus A Diepstraten, Annelot Jm Meijer, Martine van Grotel

|Sep 07, 2021
The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.

Annelot J M Meijer, Kathy H Li, Beth Brooks

|Jul 15, 2021
TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study.

A J M Meijer, F A Diepstraten, T Langer

|Nov 16, 2020
Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study.

Annelot J M Meijer, Marta F Fiocco, Geert O Janssens

|Mar 20, 2019
Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study.

Eva Clemens, Annelot Jm Meijer, Linda Broer

Pageof 1

Frequent Collaborators

3 joint publications

Franciscus A Diepstraten

3 joint publications

Marry M van den Heuvel-Eibrink

2 joint publications

André G Uitterlinden

2 joint publications

Henrik Hasle